First Report of Autologous Cord Blood Transplantation in the Treatment of a Child with Leukemia
Ammar Hayani, Eberhard Lampeter, David Viswanatha, David Morgan and Sharad N. Salvi.
Pediatrics 2007;119;296-300

ABSTRACT
We present the case of a 3-year-old girl with acute lymphoblastic leukemia who developed isolated central nervous system relapse while receiving chemotherapy 10 months after diagnosis. The child achieved a second remission on retreatment with systemic and intrathecal chemotherapy. She then underwent myeloablative chemotherapy and radiation therapy followed by infusion of her own umbilical cord blood, which the parents had saved after her delivery. She is now doing well and is in complete remission 20 months after cord blood transplantation. In this first report of autologous cord blood transplantation for treatment of childhood leukemia, we discuss the safety and feasibility of this procedure as well as some of the uncertainties surrounding autologous cord blood collection and usage.
 

Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children
(Ensaio Clínico NCT00254722)

The Application of Umbilical Cord Blood Cells in the Treatment of Diabetes Mellitus
Tomas Koblas, S. Mitchell Harman and Frantisek Saudek.
The Review of Diabetic Studies 2005; Vol.2; No. 4; 228 – 234.

ABSTRACT
In recent years, human umbilical cord blood (HUCB) has emerged as an attractive tool for ell-based therapy. Although at present the clinical application of HUCB is limited to the ields of hematology and oncology, a rising number of studies show potential for further pplication in the treatment of non-hematopoietic diseases. HUCB, with its real abundance, simple collection procedure and no serious ethical dilemmas, represents a valuable alternative to the use of other stem cell sources. The aim of this article is to review the literature on HUCB and to assess its eventual usability in the treatment of diabetes mellitus. This review presents some recent reports concerning pancreatic endocrine stem cells and their identification, HUCB stem cells and their advantages and, finally, the potential for converting HUCBderived stem cells into insulin-producing β-cells.
 

Umbilical Cord Blood Infusion to Treat Type 1 Diabetes
(Ensaio Clinico NCT00305344)